Medication topics
Etrasimod articles covering S1P-modulator therapy, safety, approvals, access, and IBD treatment decisions. Access context emphasizes approvals, coverage, affordability, availability, and policy decisions.
5 articles
If you or someone you care for uses or may use VELSIPITY (etrasimod) for ulcerative colitis, local manufacturing and priority review in China could improve drug supply, availability, and potentially lower costs. The...
This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
